Hygieia Biotech Unveils Clinical Ca-AKG at CPHI Korea
EnerLive® Ca-AKG Human RCT Clinical Data & Multi-Target Efficacy Validation
Discover the world's first multi-target human clinical Ca-AKG (Trial ID: NCT07114536). Backed by human double-blind RCT data, exclusive patented enzymatic synthesis, and sustained-release liposomal delivery, EnerLive® sets a new standard for cellular vitality, bone & joint regeneration, and biological anti-aging.
At CPHI Korea 2026, Hygieia Biotech Co., Ltd. presented landmark human clinical and in-vitro data for EnerLive® Calcium Alpha-Ketoglutarate (Ca-AKG). Registered under human double-blind RCT Clinical Trial Registry ID: NCT07114536, this ingredient sets a new industry standard for clinical substantiation in healthy longevity.
Clinically Validated Multi-Target Efficacy:Developed through Hygieia’s exclusive patented enzymatic process and validated by comprehensive toxicological safety assessments, EnerLive® demonstrates proven biological benefits across three major health domains:
1. Cellular Anti-Aging & Telomere Health:• Telomerase activity increased by +53.2%• Total cellular antioxidant capacity increased by +44.8% to +77%
2. Bone & Joint Regeneration:• Inflammation recovery rate elevated by +69.2%• Cartilage lesion recovery rate improved by +173.9%
3. Dermal Vitality & Skincare:• Collagen synthesis promoted by +16.22%• Intracellular ROS scavenging rate achieved +36.39%
Advanced Delivery & Formulation Ready:EnerLive® Ca-AKG is available in bulk powder, sustained-release granules, and liposomal delivery formats, designed for optimal pharmacokinetic absorption in finished capsules, tablets, and functional sachets. Full FDA-registered facility compliance ensures seamless international regulatory filings.
Visit Hygieia Biotech at Booth F28 during CPHI Korea 2026 to review our full clinical trial dossiers and request on-site evaluation samples.
